TY - DATA T1 - Incremental cost-effectiveness ratios of including pre-adolescent boys in the childhood vaccination program compared to vaccination of pre-adolescent girls only. PY - 2014/03/20 AU - Emily A. Burger AU - Stephen Sy AU - Mari Nygård AU - Ivar S. Kristiansen AU - Jane J. Kim UR - https://plos.figshare.com/articles/dataset/_Incremental_cost_effectiveness_ratios_of_including_pre_adolescent_boys_in_the_childhood_vaccination_program_compared_to_vaccination_of_pre_adolescent_girls_only_/969048 DO - 10.1371/journal.pone.0089974.t003 L4 - https://ndownloader.figshare.com/files/1429020 KW - Computational biology KW - Population modeling KW - Infectious disease modeling KW - immunology KW - Vaccination and immunization KW - vaccines KW - Cancer vaccines KW - epidemiology KW - Economic epidemiology KW - Infectious disease epidemiology KW - health care KW - Health economics KW - Infectious diseases KW - Sexually transmitted diseases KW - Human papillomavirus infection KW - Viral diseases KW - oncology KW - Cancers and neoplasms KW - Genitourinary tract tumors KW - Head and neck tumors KW - Cancer prevention KW - urology KW - Genitourinary infections KW - women's health KW - Obstetrics and gynecology KW - Gynecologic cancers KW - Economics KW - Economic analysis KW - Cost-effectiveness analysis KW - cost-effectiveness KW - ratios KW - pre-adolescent KW - boys KW - vaccination KW - compared KW - girls N2 - aAssumes a cost per dose of $75, exclusive of the administration cost (≈$14 per dose).bCompared to no vaccination.cCompared to girls-only vaccination.dIncludes female cervical, vulvar, vaginal, anal and oropharyngeal cancers,eIncludes male anal, oropharyngeal and penile cancers,fIncludes cervical, vulvar, vaginal, anal, oropharyngeal and penile cancers related to HPV-16, -18, and genital warts and recurrent respiratory papillomatosis related to HPV-6, -11. ER -